Clinical Trial Update: Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating ruxolitinib with and without abatacept (CTLA-4Ig) for prophylaxis of graft-versus-host disease and cytokine release syndr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Graft-versus-host Disease

Drugs mentioned

• Jakafi (ruxolitinib)
• ORENCIA (ABATACEPT)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Graft Vs Host Disease, Graft-versus-host-disease | Phase 1 | Status: RECRUITING